News ASCO 25: Can GLP-1 drugs reduce cancer risk? A study has suggested the benefits of GLP-1 agonists could extend to a reduction in the risk of a slew of cancers associated with being overweight.
Patients Unifying observational research with a next-generation virtu... Observational research is core to drug development, helping researchers understand the natural history of diseases and the real-world impact of treatments on patients.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face